Talking Points and FAQs: Potential Food and Drug Administration Authorization of Novavax COVID-19 Vaccine (English, Spanish)

Talking Points and FAQs: Potential Food and Drug Administration Authorization of Novavax COVID-19 Vaccine (English, Spanish)

Date posted: June 15, 2022
Last reviewed: June 15, 2022

The Public Good Projects in collaboration with the Hispanic Communications Network

Talking points and FAQs discuss the potential for an upcoming authorization by the Food and Drug Administration (FDA) for the two-dose Novavax COVID-19 vaccine. The FDA's advisory committee recommended the use of the Novavax vaccine in the U.S. If authorized by the FDA, the vaccine would still need to be recommended by the Centers for Disease Control and Prevention (CDC). The talking points discuss the vaccine's effectiveness and concerns about the rare but serious risk of heart inflammation as a side effect of the vaccine, similar to mRNA COVID-19 vaccines. The talking points explain that the Novavax vaccine is protein-based, which is a different design from other COVID-19 vaccines currently approved for use in the U.S. The Novavax vaccine may serve as a crucial option for people who are allergic to the ingredients used in mRNA vaccines. The FAQs cover similar information. A related graphic is available here: Social Media: Graphic About the Novavax COVID-19 Vaccine (English, Spanish).

Download
Report